Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 18/20 | 0.41 |
| ▸ | DRD1 | P21728 | 13/20 | 0.41 |
| ▸ | DRD4 | P21917 | 2/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | DRD5 | P21918 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23125443 | 0.92 | DRD2 (0.41) | DRD2DRD1DRD4HRH4 | |
| SCHEMBL15047809 | 0.91 | DRD2 (0.40) | DRD2DRD1DRD4HRH4 | |
| SCHEMBL24199398 | 0.90 | DRD2 (0.40) | DRD2DRD1DRD4HRH4 | |
| SCHEMBL20751555 | 0.90 | DRD2 (0.40) | DRD2DRD1DRD4HRH4 | |
| SCHEMBL23125445 | 0.90 | DRD2 (0.44) | DRD2DRD1HRH4 | |
| SCHEMBL20751621 | 0.87 | DRD2 (0.38) | DRD2DRD1DRD4HRH4 | |
| SCHEMBL23125441 | 0.82 | DRD1 (0.40) | DRD2DRD1DRD4HRH4 | |
| SCHEMBL15047808 | 0.82 | DRD2 (0.39) | DRD2DRD1DRD4HRH4 | |
| SCHEMBL20751562 | 0.81 | DRD2 (0.38) | DRD2DRD1DRD4HRH4 | |
| SCHEMBL20751674 | 0.80 | DRD1 (0.38) | DRD2DRD1DRD4ADRA2ADRD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11225490-B2 | Prodrugs of secondary amine compounds | ALKERMES PHARMA IRELAND LIMITED (IE) | 2022-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11225490-B2 | Prodrugs of secondary amine compounds | HNMT, MAOB, UGT1A1 | DRD2 548/4885DRD1 1492/4885DRD4 858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.